The developing role of pharmacist prescribers
Highlights from EBMT 2016: Immunotherapy
Are newer, targeted agents better for the management of untreated CLL than chemoimmunotherapy?
Minimal residual disease (MRD) monitoring for multiple myeloma is here to stay
Which is the best combination therapy in relapsed and refractory multiple myeloma?